|Day Low/High||165.58 / 166.81|
|52 Wk Low/High||94.82 / 165.95|
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
It has been a better year for the Russell 2000 and the small-caps it represents.
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
Straying from these names could land you in quicksand as the 4th quarter begins.
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
I think M&A activity will pick up markedly going forward across the industry.
A look at three names to consider in the biotech and biopharma space.
Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.
These favorite names in the volatile sector offer the potential for high rewards.
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
The path of least resistance is downward for Alexion.
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
Stocks edged higher in cautious gains after Monday's rally pulled the Dow Jones Industrial Average and S&P 500 to their best gains in six months.
It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...
A quantitative upgrade and chart patterns may do the trick.
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
But I don't have a lot of confidence in this market beyond the intraday action.
Alexion Pharmaceuticals presents a tradeable countertrend opportunity.
"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: " The Good, the Bad and the Ugly" https://www.youtube.com/watch? v=AFa1-kciCb4 No "Takeaways" today as the action was another painfully boring, uneventful and with litt...
If you want to stay active, you'll have to do more homework.
"There are two kinds of spurs, my friend. Those that come in by the door; those that come in by the window.." -- Tuco, " The Good, the Bad and the Ugly" No "Takeaways" today as the action was kinda boring, uneventful and with little individual stock...
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...
Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.